Morningstar
•
Mar 06, 2026
AstraZeneca PLC: AstraZeneca Earnings: Strong Finish to Year, and Busy Schedule of Data Readouts Ahead
Summary
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Moderna, Inc.
May 01, 2026
•
MRNA
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Bristol-Myers Squibb Company
Apr 30, 2026
•
BMY
Analyst Report: Eli Lilly and Company
Apr 30, 2026
•
LLY
